These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 15628299

  • 21. Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors.
    Resnicoff M, Burgaud JL, Rotman HL, Abraham D, Baserga R.
    Cancer Res; 1995 Sep 01; 55(17):3739-41. PubMed ID: 7641185
    [Abstract] [Full Text] [Related]

  • 22. beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts.
    Goel HL, Breen M, Zhang J, Das I, Aznavoorian-Cheshire S, Greenberg NM, Elgavish A, Languino LR.
    Cancer Res; 2005 Aug 01; 65(15):6692-700. PubMed ID: 16061650
    [Abstract] [Full Text] [Related]

  • 23. Antisense treatment of IGF-IR enhances chemosensitivity in squamous cell carcinomas of the head and neck.
    Liu S, Jin F, Dai W, Yu Y.
    Eur J Cancer; 2010 Jun 01; 46(9):1744-51. PubMed ID: 20451373
    [Abstract] [Full Text] [Related]

  • 24. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor.
    Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R.
    Cancer Res; 1994 Sep 15; 54(18):4848-50. PubMed ID: 8069850
    [Abstract] [Full Text] [Related]

  • 25. Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor.
    Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK, Camuso AE, Gottardis M, Greer AF, Ho CP, Hurlburt W, Li A, Saulnier M, Velaparthi U, Wang C, Wen ML, Westhouse RA, Wittman M, Zimmermann K, Rupnow BA, Wong TW.
    Cancer Res; 2005 May 01; 65(9):3781-7. PubMed ID: 15867374
    [Abstract] [Full Text] [Related]

  • 26. Knockdown of IGF-IR by Antisense Oligodeoxynucleotide auguments the sensitivity of bladder cancer cells to mitomycin.
    Sun HZ, Wu SF, Tu ZH.
    Acta Pharmacol Sin; 2001 Sep 01; 22(9):841-6. PubMed ID: 11749868
    [Abstract] [Full Text] [Related]

  • 27. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
    Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D.
    Cancer Res; 2006 Feb 15; 66(4):2391-402. PubMed ID: 16489046
    [Abstract] [Full Text] [Related]

  • 28. Insulin-like growth factor-I receptor signaling blockade combined with radiation.
    Allen GW, Saba C, Armstrong EA, Huang SM, Benavente S, Ludwig DL, Hicklin DJ, Harari PM.
    Cancer Res; 2007 Feb 01; 67(3):1155-62. PubMed ID: 17283150
    [Abstract] [Full Text] [Related]

  • 29. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo.
    Watanabe N, Takaoka M, Sakurama K, Tomono Y, Hatakeyama S, Ohmori O, Motoki T, Shirakawa Y, Yamatsuji T, Haisa M, Matsuoka J, Beer DG, Nagatsuka H, Tanaka N, Naomoto Y.
    Clin Cancer Res; 2008 Jul 15; 14(14):4631-9. PubMed ID: 18628478
    [Abstract] [Full Text] [Related]

  • 30. Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice.
    Bauer TW, Fan F, Liu W, Camp ER, Yang A, Somcio RJ, Bucana CD, Singh R, Ellis LM.
    Ann Surg Oncol; 2007 Oct 15; 14(10):2838-46. PubMed ID: 17653802
    [Abstract] [Full Text] [Related]

  • 31. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.
    Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M, Dunn SE.
    Cancer Res; 2008 Dec 15; 68(24):10238-46. PubMed ID: 19074892
    [Abstract] [Full Text] [Related]

  • 32. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer.
    Matsubara J, Yamada Y, Hirashima Y, Takahari D, Okita NT, Kato K, Hamaguchi T, Shirao K, Shimada Y, Shimoda T.
    Clin Cancer Res; 2008 May 15; 14(10):3022-9. PubMed ID: 18483367
    [Abstract] [Full Text] [Related]

  • 33. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    Cunningham MP, Thomas H, Marks C, Green M, Fan Z, Modjtahedi H.
    Int J Oncol; 2008 Nov 15; 33(5):1107-13. PubMed ID: 18949375
    [Abstract] [Full Text] [Related]

  • 34. Intravenous insulin-like growth factor-I receptor antisense treatment reduces angiotensin receptor expression and function in spontaneously hypertensive rats.
    Nguyen TT, Cao N, Short JL, White PJ.
    J Pharmacol Exp Ther; 2006 Sep 15; 318(3):1171-7. PubMed ID: 16751253
    [Abstract] [Full Text] [Related]

  • 35. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM.
    Cancer Res; 2005 Sep 01; 65(17):7775-81. PubMed ID: 16140945
    [Abstract] [Full Text] [Related]

  • 36. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
    Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ, Zhao Y, Pollak MN.
    Gynecol Oncol; 2006 Feb 01; 100(2):389-96. PubMed ID: 16300820
    [Abstract] [Full Text] [Related]

  • 37. Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis.
    Moser C, Schachtschneider P, Lang SA, Gaumann A, Mori A, Zimmermann J, Schlitt HJ, Geissler EK, Stoeltzing O.
    Eur J Cancer; 2008 Jul 01; 44(11):1577-86. PubMed ID: 18445520
    [Abstract] [Full Text] [Related]

  • 38. Effects of VEGFR-1, VEGFR-2, and IGF-IR hammerhead ribozymes on glucose-mediated tight junction expression in cultured human retinal endothelial cells.
    Spoerri PE, Afzal A, Li Calzi S, Shaw LC, Cai J, Pan H, Boulton M, Grant MB.
    Mol Vis; 2006 Jan 12; 12():32-42. PubMed ID: 16446700
    [Abstract] [Full Text] [Related]

  • 39. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines.
    Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D.
    Endocr Relat Cancer; 2009 Jun 12; 16(2):429-41. PubMed ID: 19153208
    [Abstract] [Full Text] [Related]

  • 40. Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
    Manara MC, Landuzzi L, Nanni P, Nicoletti G, Zambelli D, Lollini PL, Nanni C, Hofmann F, García-Echeverría C, Picci P, Scotlandi K.
    Clin Cancer Res; 2007 Feb 15; 13(4):1322-30. PubMed ID: 17317844
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.